Company / Capital Expenditures
Seres Therapeutics, Inc. Capital Expenditures History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$8.0M
FY2025
5-year range
$591.0K / $9.6M
FY2021-FY2025
Trend
-16.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 10 years, ranging from $174,000 in FY2015 to $21M in FY2018.
Based on SEC 10-K filings.
$8M in FY2025 with a 10-year CAGR of +46.6%.
Improved from $591,000 to $8M over the past 3 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +138.1%
- 5-Year CAGR
- +32.7%
- 10-Year CAGR
- +46.6%
Key checks
Key Insights
- 5-year CAGR of +32.7%, indicating consistent growth.
- In FY2025, capital expenditures decreased 16.6% year-over-year.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.0M | -16.6% |
| FY2023 | $9.6M | +1518.6% |
| FY2022 | $591.0K | -41.0% |
| FY2021 | $1.0M | -48.3% |
| FY2020 | $1.9M | -58.6% |
| FY2019 | $4.7M | -78.2% |
| FY2018 | $21.5M | +392.7% |
| FY2017 | $4.4M | +335.8% |
| FY2016 | $1.0M | +475.3% |
| FY2015 | $174.0K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026